Orginal Article |
|
|
|
|
Research Progress of Key Techniques for Severe/Critical Type of Novel Coronavirus Pneumonia |
PAN Tong-tong,CHEN Yong-ping() |
Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, Hepatology Institute of Wenzhou Medical University, Wenzhou 325035, China |
|
|
Abstract The pneumonia epidemic caused by the new coronavirus (SARS-CoV-2) seriously threatens the health and life of the general public, and has a major impact on China’s economic development and social stability. Because the new coronavirus is highly contagious, spreads fast, and has a high lethality rate, there are no effective vaccines and drugs to prevent and treat it. A small number of patients have developed severe and critical illness or even died. How to accurately resist and block the progression of new coronary pneumonia, and improve the prognosis of patients is the current research hotspot in the medical and health field. This article reviews the recent advances in the latest treatments for pneumonia in severe and critically new coronavirus infections.
|
Received: 07 February 2020
Published: 27 March 2020
|
|
Corresponding Authors:
Yong-ping CHEN
E-mail: 13505777281@163.com
|
|
|
[1] |
Huang C, Wang Y, Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020. doi: 10.1016/s0140-6736(20)30183-5.
doi: 10.1016/s0140-6736(20)30183-5
|
|
|
[2] |
Zumla A, Chan Jf, Azhar Ei , et al. Coronaviruses - drug discovery and therapeutic options. Nature Reviews Drug Discovery, 2016,15:327-347.
|
|
|
[3] |
Xu X, Chen P, Wang J , et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences, 2020. doi: 10.1007/s11427-020-1637-5.
doi: 10.1007/s11427-020-1637-5
|
|
|
[4] |
Riccio F, Talapatra S, Oxenford S , et al. Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases. Biology Open 2019,8. doi: 10.1242/bio.037663.
doi: 10.1242/bio.037663
|
|
|
[5] |
Chu C M, Cheng V C, Hung I F , et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 2004,59:252-256.
|
|
|
[6] |
Sheahan T P, Sims A C, Leist S R , et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 2020,11:222.
|
|
|
[7] |
Holshue M L, Debolt C, Lindquist S , et al. First case of 2019 novel coronavirus in the United States. The New England Journal of Medicine, 2020. doi: 10.1056/NEJMoa2001191.
doi: 10.1056/NEJMoa2001191
|
|
|
[8] |
Chen N, Zhou M, Dong X , et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England), 2020. doi: 10.1016/s0140-6736(20)30211-7.
doi: 10.1016/s0140-6736(20)30211-7
|
|
|
[9] |
Hassanein T I, Schade R R, Hepburn I S . Acute-on-chronic liver failure: extracorporeal liver assist devices. Current Opinion in Critical Care, 2011,17:195-203.
|
|
|
[10] |
Plock J A, Schnider J T, Solari M G , et al. Perspectives on the use of mesenchymal stem cells in vascularized composite allotransplantation. Frontiers in Immunology, 2013,4:175.
|
|
|
[11] |
Nikzad R, Angelo L S, Aviles-Padilla K , et al. Human natural killer cells mediate adaptive immunity to viral antigens. Science Immunology, 2019,4. doi: 10.1126/sciimmunol.aat8116.
doi: 10.1126/sciimmunol.aat8116
|
|
|
[12] |
Zhou K, Wang J, Li A , et al. Swift and strong NK cell responses protect 129 mice against high-dose influenza virus infection. Journal of Immunology (Baltimore, Md: 1950), 2016,196:1842-1854.
|
|
|
[13] |
Sivori S, Meazza R, Quintarelli C , et al. NK cell-based immunotherapy for hematological malignancies. Journal of Clinical Medicine, 2019,8(10):1702.
|
|
|
[14] |
Groves H T, Cuthbertson L, James P , et al. Respiratory disease following viral lung infection alters the murine gut microbiota. Frontiers in Immunology, 2018,9:182.
|
|
|
[15] |
Hao Q, Dong B R, Wu T . Probiotics for preventing acute upper respiratory tract infections. The Cochrane Database of Systematic Reviews, 2015,CD006895. doi: 10.1002/14651858.CD006895.pub3.
doi: 10.1002/14651858.CD006895.pub3
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|